Morgan Stanley Initiates Coverage On Q32 Bio with Overweight Rating, Announces Price Target of $34

Benzinga Newsdesk www.benzinga.com Neutral 49.5%

Neg 0% Neu 49.5% Pos 0%

Morgan Stanley analyst Judah Frommer initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Overweight rating and announces Price Target of $34.